ClinicalTrials.gg
CompletedNCT04093752Updated Jan 6, 2023Results posted

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

A Phase 3 interventional study of Tirzepatide and Insulin Glargine in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 67 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
917
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 13 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Enrollment
7th of 43
917 · median 160
Started
2019
with 7 others
Phase 3
17 of 43
1 open now
Registered
14th of 43
by date
Lead sponsor
31 of 43
Eli Lilly and Company

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 8 that started in 2019, is one of 17 in phase 3, and was the 14th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Treated with stable metformin with or without a sulfonylurea (metformin ≥1000 milligrams/day; sulfonylurea should be at least half the maximum dose) for at least 2 months
  • Are insulin-naive (except for the use of insulin for treatment of gestational diabetes or short-term use [≤14 consecutive days] for acute conditions)
  • ≥7.5% to ≤11.0% at screening
  • Stable weight (±5%) ≥3 months, and agree to not initiate a diet and/or exercise program during the study with the intent of reducing body weight other than the lifestyle and dietary measures for diabetes treatment
  • (BMI) ≥23 kilograms per meter squared

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Have history of chronic or acute pancreatitis
  • Have history of proliferative diabetic retinopathy; or diabetic maculopathy; or non-proliferative diabetic retinopathy that requires acute treatment
  • Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months
  • Have a history of ketoacidosis or hyperosmolar state/coma
  • Have a known gastric emptying abnormality, have undergone or plan to have during the course of the study, or chronically take drugs that directly affect GI motility
  • Have acute myocardial infarction (MI), stroke or hospitalization due to congestive heart failure (CHF) within 2 months
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  • Have been treated with prescription drugs that promote weight loss or similar other body weight loss medications including over the counter (OTC) within 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
917 participants (actual)

Study arms

  • Experimental
    5 mg Tirzepatide

    Participants received 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW).

    Drug: Tirzepatide

  • Experimental
    10 mg Tirzepatide

    Participants received 10 mg tirzepatide administered SC QW.

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    Participants received 15 mg tirzepatide administered SC QW.

    Drug: Tirzepatide

  • Active comparator
    Insulin Glargine

    Participants received insulin glargine administered once daily (QD) SC. The starting dose of insulin glargine was 6 Insulin Units (IU)/day at bedtime, titrated to a fasting blood glucose (FBG) between 72-100 milligrams per Deciliter (mg/dL), following a treat-to-target (TTT) algorithm.

    Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Mean Change From Baseline in HbA1c (5 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Treatment + Time + Treatment\*Time (Type III sum of squares).

    Time frame: Baseline, Week 40

  2. Mean Change From Baseline in Body Weight

    LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

    Time frame: Baseline, Week 40

  3. Percentage of Participants Achieving an HbA1c Target Value of <7.0%

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 40

  4. Percentage of Participants Achieving an HbA1c Target Value of <5.7%

    HbA1c is the glycosylated fraction of hemoglobin A. Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 40

  5. Mean Change From Baseline in Fasting Serum Glucose

    Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

    Time frame: Baseline, Week 40

  6. Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values

    The SMBG data was collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post-meal, Midday Premeal, Midday 2-hour Post-meal, Evening Premeal, Evening 2-hour Post-meal and Bedtime. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

    Time frame: Baseline, Week 40

  7. Percentage of Participants Who Achieved Weight Loss ≥5%

    Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 40

  8. Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score

    DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures with Baseline + Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SU) + Treatment (Type III sum of squares) as covariates.

    Time frame: Baseline, Week 40

  9. Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia

    The hypoglycemia events were defined by participant reported events with blood glucose \< 54 mg/dL \[\<3.0 Millimole per Liter (mmol/L)\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of post-baseline hypoglycemia was estimated by negative binomial model: Number of episodes = Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.

    Time frame: Baseline through end of safety follow-up (Up To Week 44)

07

Results

Posted Jan 6, 2023

Participant flow

Participant flow — Overall Study
Milestone5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Started230228229230
Received at least one dose of study drug230228229220
Completed213201200201
Not completed17272929
Withdrew: Adverse event719184
Withdrew: Withdrawal by subject66820
Withdrew: Lost to follow-up2111
Withdrew: Death0012
Withdrew: Participant could not continue due to work related reasons0101
Withdrew: Covid 190001
Withdrew: Participant thought there were too many adverse events0010
Withdrew: Participant was reluctant to follow-up1000
Withdrew: Participant did not come for the visit1000

Outcome measures

PrimaryMean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed model repeated measures (MMRM) model with covariates Baseline + Country + Baseline Oral Antihyperglycemic Medication (OAM) Use (Metformin (Met), Met plus Sulfonylurea (SU)) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)
Percentage of HbA1c10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)-2.44 ± 0.073-2.49 ± 0.072-0.95 ± 0.073
Statistical analysis
  • 10 mg Tirzepatide vs Insulin Glargine · Ls mean difference: -1.49 · 95% CI -1.69 to -1.29
  • 15 mg Tirzepatide vs Insulin Glargine · Ls mean difference: -1.54 · 95% CI -1.74 to -1.34
SecondaryMean Change From Baseline in HbA1c (5 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model with covariates Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Treatment + Time + Treatment\*Time (Type III sum of squares).

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Percentage of HbA1c
Mean Change From Baseline in HbA1c (5 mg)
Percentage of HbA1c5 mg TirzepatideInsulin Glargine
Mean Change From Baseline in HbA1c (5 mg)-2.24 ± 0.070-0.95 ± 0.073
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Ls mean difference: -1.29 · 95% CI -1.49 to -1.09
SecondaryMean Change From Baseline in Body Weight

LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Baseline in Body Weight
kilograms (kg)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Mean Change From Baseline in Body Weight-5.0 ± 0.32-7.0 ± 0.33-7.2 ± 0.331.5 ± 0.33
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.5 · 95% CI -7.4 to -5.6
  • 10 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -8.5 · 95% CI -9.5 to -7.6
  • 15 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -8.7 · 95% CI -9.6 to -7.7
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <7.0%

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 40
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an HbA1c Target Value of <7.0%
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Percentage of Participants Achieving an HbA1c Target Value of <7.0%75.4486.0484.3823.72
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 14.54 · 95% CI 8.94 to 23.64
  • 10 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.76 · 95% CI 16.72 to 49.49
  • 15 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.27 · 95% CI 14.88 to 42.95
SecondaryPercentage of Participants Achieving an HbA1c Target Value of <5.7%

HbA1c is the glycosylated fraction of hemoglobin A. Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 40
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an HbA1c Target Value of <5.7%
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Percentage of Participants Achieving an HbA1c Target Value of <5.7%14.9120.7227.680.00
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = 0.002 · Odds ratio (or): 82.54 · 95% CI 5.13 to 1327.81
  • 10 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 124.76 · 95% CI 7.79 to 1997.01
  • 15 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 184.90 · 95% CI 11.59 to 2950.73
SecondaryMean Change From Baseline in Fasting Serum Glucose

Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Mean Change From Baseline in Fasting Serum Glucose
milligrams per deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Mean Change From Baseline in Fasting Serum Glucose-58.6 ± 2.13-66.2 ± 2.19-64.8 ± 2.19-46.2 ± 2.19
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -12.3 · 95% CI -18.3 to -6.3
  • 10 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -20.0 · 95% CI -26.1 to -13.9
  • 15 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -18.6 · 95% CI -24.6 to -12.5
SecondaryMean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values

The SMBG data was collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post-meal, Midday Premeal, Midday 2-hour Post-meal, Evening Premeal, Evening 2-hour Post-meal and Bedtime. LS mean was determined by MMRM model with Baseline + Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment + Time + Treatment\*Time (Type III sum of squares) as covariates.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
milligrams per deciliter (mg/dL)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Mean Change in Daily Glucose Average From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values-77.0 ± 2.09-83.4 ± 2.16-84.6 ± 2.18-42.8 ± 2.18
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -34.2 · 95% CI -40.1 to -28.3
  • 10 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -40.6 · 95% CI -46.7 to -34.6
  • 15 mg Tirzepatide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -41.8 · 95% CI -47.9 to -35.8
SecondaryPercentage of Participants Who Achieved Weight Loss ≥5%

Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 40
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Weight Loss ≥5%
Percentage of participants5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Percentage of Participants Who Achieved Weight Loss ≥5%55.7071.6274.115.58
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 21.89 · 95% CI 11.63 to 41.20
  • 10 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 43.79 · 95% CI 22.96 to 83.50
  • 15 mg Tirzepatide vs Insulin Glargine · Regression, Logistic · p = <0.001 · Odds ratio (or): 48.41 · 95% CI 25.34 to 92.49
SecondaryDiabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score

DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The treatment satisfaction score ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS mean was determined by ANCOVA model for endpoint measures with Baseline + Country + Baseline HbA1c Group (\<=8.5%, \>8.5%) + Baseline OAM Use (Met, Met plus SU) + Treatment (Type III sum of squares) as covariates.

Time frame:
Baseline, Week 40
Reported as:
Least squares mean · Units on a scale
Diabetes Treatment Satisfaction as Measured by the Diabetes Treatment Satisfaction Questionnaire, Change Version (DTSQc) Hyperglycemia, Hypoglycemia and Treatment Satisfaction Score
Units on a scale5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Hyperglycemia-1.8 ± 0.12-2.1 ± 0.12-2.0 ± 0.12-1.3 ± 0.12
Hypoglycemia-1.9 ± 0.11-1.9 ± 0.12-2.0 ± 0.12-1.8 ± 0.12
Treatment Satisfaction Score16.0 ± 0.2715.8 ± 0.2815.9 ± 0.2914.2 ± 0.28
Statistical analysis
  • 5 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = 0.007 · Ls mean difference: -0.47 · 95% CI -0.81 to -0.13
  • 10 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = <0.001 · Ls mean difference: -0.77 · 95% CI -1.11 to -0.43
  • 15 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = <0.001 · Ls mean difference: -0.71 · 95% CI -1.05 to -0.36
  • 5 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = 0.384 · Ls mean difference: -0.14 · 95% CI -0.46 to 0.18
  • 10 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = 0.307 · Ls mean difference: -0.17 · 95% CI -0.49 to 0.16
  • 15 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = 0.184 · Ls mean difference: -0.22 · 95% CI -0.55 to 0.11
  • 5 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = <0.001 · Ls mean difference: 1.81 · 95% CI 1.03 to 2.59
  • 10 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = <0.001 · Ls mean difference: 1.63 · 95% CI 0.84 to 2.41
  • 15 mg Tirzepatide vs Insulin Glargine · ANCOVA · p = <0.001 · Ls mean difference: 1.68 · 95% CI 0.89 to 2.47
SecondaryRate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia

The hypoglycemia events were defined by participant reported events with blood glucose \< 54 mg/dL \[\<3.0 Millimole per Liter (mmol/L)\] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of post-baseline hypoglycemia was estimated by negative binomial model: Number of episodes = Country + Baseline OAM Use (Met, Met plus SU) + Baseline HbA1c Group (\<= 8.5%, \>8.5%) + Treatment, with log (exposure in days/365.25) as an offset variable.

Time frame:
Baseline through end of safety follow-up (Up To Week 44)
Reported as:
Mean · Episodes/participant/365.25 days
Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia
Episodes/participant/365.25 days5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Rate of Hypoglycemia With Blood Glucose < 54 mg/dL or Severe Hypoglycemia0.0658 ± 0.026030.0890 ± 0.031960.0700 ± 0.022730.0538 ± 0.01594

Adverse events

Collected over Baseline Through End of Safety Follow-Up (Up To Week 44).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide0/230 (0%)15/230 (6.5%)174/230 (75.7%)
10 mg Tirzepatide0/228 (0%)14/228 (6.1%)201/228 (88.2%)
15 mg Tirzepatide1/229 (0.4%)15/229 (6.6%)193/229 (84.3%)
Insulin Glargine2/220 (0.9%)20/220 (9.1%)83/220 (37.7%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Cerebral infarctionNervous system disorders3/2300/2282/2291/220
Ectopic pregnancyPregnancy, puerperium and perinatal conditions1/960/1020/1000/102
Ovarian germ cell teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/960/1021/1000/102
AdenomyosisReproductive system and breast disorders0/960/1020/1001/102
VertigoEar and labyrinth disorders0/2300/2281/2292/220
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2302/2280/2290/220
Vertebrobasilar insufficiencyNervous system disorders0/2300/2282/2291/220
EpididymitisInfections and infestations0/1340/1260/1291/118
Atrial fibrillationCardiac disorders0/2300/2280/2291/220
Coronary artery diseaseCardiac disorders0/2300/2280/2291/220
Most frequent other events
Showing 10 of 18
Most frequent other events
Event5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin Glargine
Decreased appetiteMetabolism and nutrition disorders74/230109/228102/2290/220
DiarrhoeaGastrointestinal disorders77/230103/228101/2293/220
NauseaGastrointestinal disorders46/23075/22873/2295/220
VomitingGastrointestinal disorders21/23034/22829/2293/220
Abdominal distensionGastrointestinal disorders19/23025/22834/2292/220
Lipase increasedInvestigations32/23032/22830/2296/220
HyperuricaemiaMetabolism and nutrition disorders27/23028/22827/22924/220
DizzinessNervous system disorders10/23013/22824/22910/220
FlatulenceGastrointestinal disorders20/23023/22818/2292/220
FatigueGeneral disorders12/23023/22817/2293/220

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
Mean53.10 ± 11.2553.50 ± 11.1454.30 ± 11.6555.60 ± 11.4054.10 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
Female96102100102400
Male134126129118507
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
Hispanic or Latino00000
Not Hispanic or Latino00000
Unknown or Not Reported230228229220907
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
American Indian or Alaska Native00000
Asian225225226216892
Native Hawaiian or Other Pacific Islander20305
Black or African American00000
White330410
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
Australia533415
China190192190184756
India979732
South Korea26262725104
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)5 mg Tirzepatide10 mg Tirzepatide15 mg TirzepatideInsulin GlargineTotal
Mean8.77 ± 0.9768.70 ± 0.9558.67 ± 0.9608.68 ± 0.9348.71 ± 0.956
08

Study locations

67 sites
  • Paratus Clinical Research Western Sydney
    Blacktown, New South Wales 2148, Australia
  • Paratus Clinical Research Central Coast
    Kanwal, New South Wales 2259, Australia
  • Holdsworth House Medical Practice
    Sydney, New South Wales 2010, Australia
  • Illawarra Shoalhaven Local Health District
    Wollongong, New South Wales 2500, Australia
  • Core Research Group
    Milton, Queensland 4064, Australia
  • Barwon Health - The Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Adelaide Medical Solutions
    Woodville South, 5011, Australia
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Huizhou Municipal Central Hospital
    Huizhou, Guangdong 516001, China
  • Cangzhou People's Hospital
    Cangzhou, Hebei 061600, China
  • Hebei Medical University
    Hengshui Shi, Hebei 053000, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou Shi, Henan 450014, China
  • The First People's Hospital of Yueyang
    Yueyang, Hunan 414000, China
  • Bao Tou Central Hospital
    Bao Tou, Inner Mongolia 014040, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213003, China
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210000, China
  • The First Hospital of Nanjing
    Nanjing, Jiangsu 210006, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210009, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nanjing Medical University - Nanjing Jiangning Hospital
    Nanjing, Jiangsu 211100, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215066, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212000, China
  • The Third Hospital of Nanchang
    Nanchang, Jiangxi 330009, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Dalian University - The Affiliated Zhongshan Hospital
    Dalian, Liaoning 116001, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • 1st affiliated Hospital of Shanxi Medical University
    Tai Yuan, Shan XI 030001, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Qingdao Central Hospital
    Qingdao, Shandong 266042, China
  • Shanghai 6th people's hospital
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of Xi'an Medical University
    XI 'an, Shanxi, China
  • West China Hospital Sichuan University
    Chengdu, Sichuan 610041, China
  • Chengdu Fifth People's Hospital
    Chengdu, Sichuan 611130, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Chongqing Three Gorges Central Hospital
    Wanzhou, Wanzhou 404199, China
  • Chongqing General Hospital
    Chongqing, Yuzhong District 400014, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang 313000, China
  • Shaoxing People's Hospital
    Shaoxing, Zhejiang 312000, China
  • Beijing Peking Union Medical College Hospital
    Beijing, 100730, China
  • Beijing Pinggu District Hospital
    Beijing, 101200, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, 102202, China
  • Pingxiang People's Hospital
    Pingxiang, 337000, China
  • Shanghai Putuo District Center Hospital
    Shanghai, 200062, China
  • Tianjin People's Hospital
    Tianjin, 300121, China
  • The Fourth People's Hospital of Zigong City
    Zigong, China
  • King Edward Memorial Hospital and Research Center
    Mumbai, Maharashtra 400012, India
  • BSES Municipal General Hsptl
    Mumbai, Maharashtra 400058, India
  • Apollo Gleneagles Hospitals Kolkata
    Kolkata, West Bengal 700054, India
  • Fortis Hospital
    Delhi, 110088, India
  • Kyung Hee University Hospital
    Seoul, Gangdong-gu 02447, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, Geonggi-do 13620, Korea, Republic of
  • Bucheon St. Mary's Hospital
    Bucheon,, Gyeonggi-do 14647, Korea, Republic of
  • Hanyang University Guri Hospital
    Guri-si, Gyeonggido 11923, Korea, Republic of
  • Yonsei University Wonju Severance Christian Hospital
    Gangwon-do, Korea 220-701, Korea, Republic of
  • Ulsan University Hospital
    Ulsan, Korea 44033, Korea, Republic of
  • Inje University Sanggye Paik Hospital
    Seoul, Seoul-teukbyeolsi 01757, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Seoul-teukbyeolsi 02841, Korea, Republic of
  • Keimyung University Dongsan Hospital
    Daegu, Taegu-Kwangyǒkshi 41931, Korea, Republic of
  • Korea University Ansan Hospital
    Ansan-si, 15355, Korea, Republic of
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Hallym University Kangnam Sacred Heart Hospital
    Seoul, 07441, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2021, 22 months.

Results were first posted in Jan 2023, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 22 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2019
First posted
Sep 18, 2019
StartActual
Dec 9, 2019
Primary completionActual
Nov 1, 2021
CompletionActual
Nov 24, 2021
Results first posted
Jan 6, 2023
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04093752
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Dec 9, 2019
Primary completion
Nov 1, 2021
Completion
Nov 24, 2021
Results posted
Jan 6, 2023
Last update
Jan 6, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion